| Vol. 6.22 – 17 June, 2022 |
| |
|
|
| MiR-690 directly inhibited fibrogenesis in hepatic stellate cells, inflammation in recruited hepatic macrophages, and de novo lipogenesis in hepatocytes. [Cell Metabolism] |
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators reported that a mitochondrial protein FUN14 domain containing 2 (FUNDC2) was transcriptionally upregulated in primary mouse liver tumors, and in approximately 40% of human HCC. [Nature Communications] |
|
|
|
| The authors introduced a platform for routine grafting of liver and other tissues on an in vitro grown microvascular bed. [Angiogenesis] |
|
|
|
| Scientists found that activation of hepatocyte p53 created a microenvironment prone to tumor formation from hepatic progenitor cells and that optimization of p53 activity in hepatocytes was important to prevent chronic liver disease patients from hepatocarcinogenesis. [Cancer Research] |
|
|
|
| Intact PPARα activity in hepatocytes was required for the cross-talk between adipose tissues and the liver during fat mobilization. [Cell Reports] |
|
|
|
| Investigators reported that Calpain-2 promoted the proliferation and invasion of HCC, and showed a positive correlation with the levels of invasion-related markers. [Oncogene] |
|
|
|
| Researchers reported that exosomal miR-411-5p from M2 macrophages inhibited hepatic stellate cells activation and miR-411-5p directly downregulated the expression of calmodulin regulated spectrin associated protein 1 (CAMSAP1) to inactivate stellate cells. [iScience] |
|
|
|
| The authors reported that silencing PRDX1 increased the accumulation of ferrous ions and lipid peroxidation accumulation in HEPG2 cells and promoted ferroptosis in hepatocellular carcinoma. [Scientific Reports] |
|
|
|
| Scientists revealed that PLIN2 was frequently upregulated in HCC cells and tissues, and increased PLIN2 expression was associated with poor prognosis outcomes in HCC. [Experimental Cell Research] |
|
|
|
| HepG2 and SMMC7721 cells were treated with 1.7%, 3.4%, and 5.1 % sevoflurane for six hours. Cell migration was analyzed using invasion, migration, and scratch assays. [Cell Transplantation] |
|
|
|
|
|
| Investigators review COVID-19 liver manifestations and pathophysiological aspects related to SARS-CoV-2 infection in patients without liver disease as well as the impact of COVID-19 in patients with chronic liver disease, particularly cirrhosis and liver transplantation. [Gut] |
|
|
|
| The authors discuss the pros and cons of different immune therapies, observed in patients with chronic hepatitis B (CHB) during the last 30 years, to derive insights into the development of an evidence-based, effective, and patient-friendly regimen of immune therapy for the treatment of CHB. [Journal of Gastroenterology] |
|
|
|
| Syndecan-1 represents the major proteoglycan of the liver, expressed by hepatocytes and cholangiocytes, and its elevated expression is a characteristic feature of liver diseases. [American Journal of Physiology-Cell Physiology] |
|
|
|
|
| Surrozen, Inc. announced that the first subject has been dosed in its two-part Phase I clinical trial for SZN-043 which is in development for the potential treatment of severe alcoholic hepatitis. [Surrozen, Inc.] |
|
|
|
|
| September 19 – 20, 2022 Vejle, Denmark |
|
|
|
|
|
| European Molecular Biology Laboratory – Heidelberg, Germany |
|
|
|
| University of Pittsburgh School of Medicine – Pittsburgh, Pennsylvania, United States |
|
|
|
| German Cancer Research Center in the Helmholtz Association – Heidelberg, Germany |
|
|
|
| La Jolla Institute for Immunology – La Jolla, California, United States |
|
|
|
| Norwegian University of Science and Technology -Trondheim, Norway |
|
|
|
|